Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Chief Executive Officer | November 03, 2025 | November 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TherapeuticsMD, Inc.
Report date November 03, 2025 · Filed November 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2035-11-03 | Direct | 67,492 |
Reported balance
After 2025-11-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-03 · Grant · Acquired 67,492 · Balance 67,492 F1: Underlying shares each vested on November 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Underlying shares each vested on November 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2021 Filed Jul 2, 2021 21:48 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantPerformance Stock Units · Derivative | 346,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-007117 · ownership.xml · derivative · entry 1 Walker Marlan D · CIK 0001820187 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,667 Underlying: Common Stock · 346,667 shares Expires not disclosed F1 · shares: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.expiration_date: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.underlying_shares: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · balance_after: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| May 11, 2021 Filed May 13, 2021 00:43 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 21,592 | $1.04 | $22,455.68 |
DisclosureSEC source: 0001387131-21-005570 · ownership.xml · nonDerivative · entry 2 Walker Marlan D · CIK 0001820187 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,908 F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $1.03 to $1.06 for an average weighted sale price of $1.04. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2021 Filed May 13, 2021 00:43 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 50,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-005570 · ownership.xml · derivative · entry 3 Walker Marlan D · CIK 0001820187 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,000 Underlying: Common Stock · 50,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 10, 2021, the reporting person received 50,500 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021. F4 · shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. F5 · derivative.exercise_date: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023. F5 · derivative.expiration_date: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023. F4 · balance_after: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. Read SEC document |
| May 10, 2021 Filed May 13, 2021 00:43 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 50,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-005570 · ownership.xml · nonDerivative · entry 1 Walker Marlan D · CIK 0001820187 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On May 10, 2021, the reporting person received 50,500 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.